Pharmacologic agents in micturitional disorders.
D001418:Baclofen / Q000627:therapeutic use; D001626:Bethanechol Compounds / Q000627:therapeutic use; D003620:Dantrolene / Q000627:therapeutic use; D004025:Dicyclomine / Q000627:therapeutic use; D004809:Ephedrine / Q000627:therapeutic use; D005422:Flavoxate / Q000627:therapeutic use; D006145:Guanethidine / Q000627:therapeutic use; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use; D008333:Mandelic Acids / Q000627:therapeutic use; D008750:Methyldopa / Q000627:therapeutic use; D009388:Neostigmine / Q000627:therapeutic use; D010643:Phenoxybenzamine / Q000627:therapeutic use; D010646:Phentolamine / Q000627:therapeutic use; D010656:Phenylephrine / Q000627:therapeutic use; D010665:Phenylpropanolamine / Q000627:therapeutic use; D011413:Propantheline / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D000644:Quaternary Ammonium Compounds / Q000627:therapeutic use; D001743:Urinary Bladder / Q000187:drug effects; D014555:Urination Disorders / Q000188:drug therapy*
D001626:Bethanechol Compounds; D008333:Mandelic Acids; D000644:Quaternary Ammonium Compounds; D010643:Phenoxybenzamine; D011413:Propantheline; D010656:Phenylephrine; D010665:Phenylpropanolamine; D009388:Neostigmine; D005422:Flavoxate; D004025:Dicyclomine; D008750:Methyldopa; D011433:Propranolol; D003620:Dantrolene; D004809:Ephedrine; D001418:Baclofen; C005419:oxybutynin; D007099:Imipramine; D010646:Phentolamine; D006145:Guanethidine